Allarity Therapeutics Inc. (NASDAQ: ALLR) has dosed the first patients with stenoparib and temozolomide in a Phase 2 trial for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE